NewsRoom Articles - Page 65 of 230

ThursdayJan 11, 2024 10:44 am

TikTok Wants to Hit $17.5B in Online US Sales in 2024

TikTok plans to expand its operations in the American e-commerce sector to roughly $17.5 billion this year. TikTok, a product by ByteDance Limited, announced its goal in recent meetings focused on its progress. The achievement of this objective would put TikTok at a better strategic position to acquire an even larger share of the e-commerce market, which is currently held by Amazon.com Inc. Unlike strategies employed by peers such as Shein and Temu, TikTok shop centers blend convenient shopping experiences with online entertainment in the United States. This strategy encourages consumers to make impulse purchases. TikTok hopes to attract more…

WednesdayJan 10, 2024 3:48 pm

Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas

A new multidisciplinary consortium is combining knowledge from several different disciplines to develop new methods for diagnosing and treating gliomas. Comprised of Sweden’s Umeå University and Umeå University Hospital and PSE Data Security from Switzerland, the consortium will amalgamate knowledge on data security, brain tumors and machine learning to potentially create new and more effective diagnostic and treatment techniques for the brain tumor. Glioma is a relatively common type of brain tumor that occurs in roughly 33% of brain tumor patients and affects around 19,000 new patients in the United States every year. Members of the consortium signed a collaboration…

TuesdayJan 09, 2024 2:54 pm

New Compound Promises Greater Efficacy Against Pain, Has No Side Effects

A newly found compound, CBD3063, has shown that it can be significantly effective at treating chronic pain in animal studies with barely any side effects. Scientists discovered the compound after screening a whopping 27 million potential drugs extensively. CBD3063 works by targeting the Cav2.2 calcium channel in a way researchers have never seen before and has shown that it can surpass existing pain-relief medications such as gabapentin in terms of efficacy. The research team published its findings in the “Proceedings of the National Academy of Sciences” (PNAS) journal. Chronic pain is an often-debilitating condition that affects 51.6 million (20.9%) of…

MondayJan 08, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Announces New Mass Spectrometry Technology Application for Chemical Manufacturing and Introduces the Pro-Control Subsidiary

Astrotech’s newest subsidiary, Pro-Control, will use the company’s mass spectrometer technology to improve purity, and yields of distilled chemicals Pro-Control delivers value by improving lost yields and delivering found profits directly to the bottom line with little, which the company believes will lead to an overall increase in profitability Astrotech believes that the Pro-Control MVP has the ability to routinely improve yields from 20% to 30% The company is introducing its proprietary ATi Mass Spectrometer Technology into the vast chemical manufacturing and process control markets Astrotech (NASDAQ: ASTC), is an instrumentation company that is focused on commercializing its proprietary ATi…

MondayJan 08, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics in May 2023 announced patent and trademark applications for its ImmunePrep commercialization platform In October 2022, the company announced patent and trademark applications for ChemoPrep and ChemoPure to enhance chemotherapy and reduce toxicity Sigyn Therapeutics in September 2022 announced plans to conduct first-in-human feasibility studies in end-stage renal disease patients In August 2022, the company commenced trading on the OTCQB Venture Market Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy(TM) to address pathogen-associated inflammatory disorders, the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies,…

FridayJan 05, 2024 1:34 pm

Five Significant Strides Made in Alzheimer’s Research in 2023

Last year was a major year for Alzheimer’s disease research. After spending decades studying the debilitating neurological condition, 2023 saw scientists make significant advancements that opened the door to an entirely new era of Alzheimer’s treatments. The condition affects an estimated 6.7 million Americans and is projected to affect close to 13 million Americans by mid-century. It typically affects people older than 65 years of age and compromises an individual’s thinking, memory, judgment, problem-solving, language and personality as it progresses. Treatments such as cognitive rehabilitation and cognitive stimulation therapy can temporarily improve symptoms, but there currently exists no cure for…

ThursdayJan 04, 2024 10:35 am

New Study Highlights Role of Mitochondria in Connecting Cancer to Dietary Fat

A research study published in the “Seminars in Cancer Biology” journal has revealed that mitochondria may play a key role in the relationship between the development of cancer and dietary fats. The study pointed to new factors that may play a role in the development and progression of medical conditions such as cancer. Interestingly, researchers found that mitochondria, organelles that produce energy for cells, may influence the link between cancer development and dietary fats. On top of sustaining a living organism, diet is also majorly responsible for their quality of life, particularly their susceptibility to various diseases and their ability…

WednesdayJan 03, 2024 10:33 am

Shining Spotlight on How Vitiligo Could Be Connected to Other Autoimmune Disorders

Vitiligo is an autoimmune condition that affects melanin, the pigmentation in the skin, and results in the development of pale-white patches on the skin. It occurs when a person’s immune system becomes dysfunctional and begins to attack melanin cells in the skin, killing the cells off and causing skin regions without pigment cells to become paler. The American Academy of Dermatology notes that there are several types of vitiligo depending on how the patches appear, how much of the skin they cover and their rate of spread. Localized vitiligo typically causes a few patches over small areas of the body,…

TuesdayJan 02, 2024 10:19 am

Study Shows Ongoing Benefits Once Immunotherapy Stops

A study from the University of Texas MD Anderson Cancer Center’s Department of Gastrointestinal Medical Oncology has found that some patients continue to benefit from immunotherapy once the treatment stops. Researchers found that some metastatic colorectal cancer patients are reluctant to stop the treatment as per their doctors’ recommendations, suggesting that discontinuing the treatment doesn’t always stop its benefits. University of Texas MD Anderson Cancer Center associate professor and senior study author Dr. Van Morris and his research team wanted to determine if the health benefits of immunotherapy continued once the treatment was discontinued or due to side effects. The…

TuesdayJan 02, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials

Clene Inc., a late clinical-stage biopharmaceutical company focused on developing solutions that improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, recently announced the publication of a peer-reviewed article The article describes results from two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8, the company’s lead drug candidate, on brain energy metabolite levels in participants with Parkinson’s Disease and Multiple Sclerosis, respectively Researchers measured key brain metabolites, such as NADH and NAD+, which are involved in neuronal energy production, utilization, and maintenance, for changes from baseline with daily, oral treatment of CNM-Au8 over…